The role of inflammation in inflammatory breast cancer

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 53-73

  Fouad, Tamer M ^a,b   Kogawa, Takahiro ^a   Reuben, James M ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APRICOXIB; CAPECITABINE; CTCE 9908; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FISH OIL; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; LAPATINIB; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; STAT PROTEIN; TETRATHIOMOLYBDIC ACID; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; JANUS KINASE 2; MESSENGER RNA; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY BREAST CANCER; MALIGNANT TRANSFORMATION; MASTECTOMY; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; DISEASE ASSOCIATION; DOWN REGULATION; EVIDENCE BASED MEDICINE; GENE EXPRESSION REGULATION; MOLECULAR DYNAMICS; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

EID: 84959231154     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_3     Document Type: Article

References (159)

1. Abrahamsson A, Morad V, Saarinen NM, Dabrosin C (2012) Estradiol, tamoxifen, and flaxseed alter IL-1beta and IL-1Ra levels in nor mal human breast tissue in vivo. J Clin Endocrinol Metab 97(11):E2044-E2054
2. ACS (2014) Cancer facts and figures 2014. American Cancer Society, Atlanta, GA. Accessed 25 Mar 2014
3. Agrawal A, Fentiman IS (2008) N SAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62(3):444-449
4. Ahern TP, Pedersen L, Tarp M et al (2011) Statin prescriptions and breast cancer recurrence risk: a Dani sh nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461-1468
5. Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol: Off J Am Soc Clin Oncol 27(13):2217-2224
6. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE (2011) Elevated pre-treatment levels of plasma C-reactive protein are associ ated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 13(3):R55
7. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9-23
8. Apte RN, Krelin Y, Song X et al (2006) Effects of micro-environment-and malignant cellderived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions . Eur J Cancer 42(6):751-759
9. Araki S, Eitel JA, Batuello CN et al (2010) TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Investig 120(1):290-302
10. Ashcroft GS (1999) Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect/Ins Pasteur 1(15):1275-1282
11. Barbieri I, Pensa S, Pannellini T et al (2010) Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of cten. Cancer Res 70(6):2558-2567
12. Bichsel VE, Liotta LA, Petricoin EF 3rd (2001) Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 7(1):69-78
13. Biswas DK, Shi Q, Baily S et al (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101(27):10137-10142
14. Biswas S, Guix M, Rinehart C et al (2007) Inhibit ion of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Investig 117(5):1305-1313
15. Black S, Kushner I, Samols D (2004) C-reactive Protein. J Biol Chem 279(47):48487-48490
16. Bozcuk H, Uslu G, Samur M et al (2004) Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic br east cancer patients treated with chemotherapy. Cytokine 27(2-3):58-65
17. Brewer TM Masuda H Iwamoto T et al 2012) Statin use and improved survival outcome in primary inflammatory breast cancer: retrospective cohort study. Paper presented at: CTRCAACR: san antonio breast cancer symposium, 4-8 Dec 2012, San Antonio, TX
18. Bristol IJ, Woodward WA, Strom EA et al (2008) Locoregional treatment outcomes after mu ltimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 72(2):474-484
19. Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol: Official J Am Soc Clin Oncol 23(12):2840-2855
20. Cabioglu N, Gong Y, Islam R et al (2007) Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann O ncol: Off J Eur Soc Med Oncol/ESMO 18(6):1021-1029
21. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB (2008) C-reactive protein and coronary heart disease: a critical review. J Intern Med 264(4):295-314
22. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ (2009) Tranilast inhibits the growth and metastasis of mammary carcinoma. Anti-Cancer Drugs 20(5):334-345
23. Charafe-Jauffret E, Ginestier C, Iovino F et al (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69(4):1302-1313
24. Charafe-Jauffret E, Ginestier C, Iovino F et al (2010) Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 16(1):45-55
25. Chen G, Gharib TG, Huang CC et al (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1(4):304-313
26. Cheshire JL, Baldwin AS Jr (1997) Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaB beta degradation. Mol Cell Biol 17(1 1):6746-6754
27. Clezardin P (2011) Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res: BCR 13(2):207
28. Criswell TL, Dumont N, Barnett JV, Arteaga CL (2008 ) Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res 68(18):7304-7312
29. D'Anello L, Sansone P, Storci G et al (2010) Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer 9:300
30. Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflamma tory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol: Official J Eur Soc Med Oncol/ESMO 22(3):515-523
31. de Jong JS, van Diest PJ, van der Valk P, Baak JP (1998) Expression of growth factors, growthinhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 184(1):53-57
32. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29(2):117-129
33. Diaz N, Minton S, Cox C et al (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res: Off J Am Assoc Cancer Res 12(1):20-28
34. Docherty NG, O'Sullivan OE, Healy DA et al (2006) TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol: Ren Physiol 290(5):F1202-F1212
35. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res: Off J Am Assoc Cancer Res 17(8):2074-2080
36. Dunning AM, Ellis PD, McBride S et al (2003) A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63(10):2610-2615
37. El-Shinawi M, Mohamed HT, El-Ghonaimy EA et al (2013) Human cytomegalovirus infection enhances NF-kappaB/p65 signaling in inflammatory breast cancer patients. PLoS ONE 8(2):e55755
38. Franco-Barraza J Valdivia-Silva JE Zamudio-Meza H et al 2010 Actin cytoskeleton participation in the onset of IL-1beta induction of an invasive mesenchymal-like phenotype in epithelial MCF-7 cellsArch Med Res 41(3 170-181
39. Freund A, Chauveau C, Brouillet JP et al (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast c ancer cells. Oncogene 22(2):256-265
40. Freund A, Jolivel V, Durand S et al (2004) Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23(36):6105-6114
41. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. New Engl J Med 340(6):448-454
42. Garcia R, Yu CL, Hudnall A et al (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ: Mol Biol J Am Assoc Cancer Res 8(12):1267-1276
43. Garcia-Tunon I, Rico te M, Ruiz A, Fraile B, Paniagua R, Royuela M (2005) IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 47(1):82-89
44. Ginestier C, Liu S, Diebel ME et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Investig 120(2):485-497
45. Gloire G, Dejardin E, Piette J (2006) Extending the nuclear roles of IkappaB kinase subunits. Biochem Pharmacol 72(9):1081-1089
46. Goel A, Aggarwal BB (2010) Curcumin, the golden spice from Indian saffron, is a chemosens itizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62(7):919-930
47. Goldberg JE, Schwertfeger KL (2010) Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11(9):1133-1146
48. Graham DJ, Campen D, Hui R et al (2005) Risk of acute myocardial infarction and sudden cardiac death in patien ts treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365(9458):475-481
49. Greenfield JP, Cobb WS, Lyden D (2010) Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas. J Clin Investig 120(3):663-667
50. Guerin M, Gabillot M, Mathieu MC et al (1989) Structure and expression of c-erbB-2 a nd EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer: J Int du Cancer 43(2):201-208
51. Haagensen C (1971) Diseases of the breast, 2nd edn. Saunders, Phi ladelphia
52. Hagedorn HG, Bachmeier BE, Nerlich AG (2001) Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (review). Int J Oncol 18(4):669-681
53. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
54. Hance KW, Anderson WF, D evesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966-975
55. Hartman ZC, Yang XY, Glass O et al (2011) HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res 71(13):4380-4391
56. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132(3):344-362
57. Health NIo (2001) APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202). http://clinicaltrials.gov/show/NCT00657137. Accessed on 4 Apr 2013
58. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1-20
59. Hinohara K, Gotoh N (2010) Inflammatory signaling pathways in self-renewing breast cancer stem cells. Curr Opin Pharmacol 10(6):650-654
60. Hirschfield GM, Pepys MB (2003) C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM: Monthly J Assoc Phys 96(11):793-807
61. Hodge DR, Peng B, Cherry JC et al (2005) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65(11):4673-4682
62. Howe LR (2007) In flammation and breast cancer, cyclooxygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res: BCR 9(4):210
63. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8(2):97-114
64. Howe LR, Subbaramaiah K, Patel J et al (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects ag ainst human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62(19):5405-5407
65. Howe LR, Chang SH, Tolle KC et al (2005) HER2/neu-induced mammary tumorigenesis and ang iogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65(21):10113-10119
66. Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693-706
67. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39(4):493-506
68. Iliopoulos D, Hirsch HA, Wang G, St ruhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108(4):1397-1402
69. Ivanovic V, Dedovic-Tanic N, Milovanovic Z et al (2009) Quantification of transforming growth factor beta 1 levels in metastatic axillary lymph node tissue extracts from breast cancer patients: a new specimen source. Anal Quant Cytol Histol/Int Acad Cytol Am Soc C ytol 31(5):288-295
70. Jablonska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jablonski J (2001) TNFalpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in ca ncer patients. Arch Immunologiae et Ther Exp 49(1):63-69
71. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms Nature reviews. Drug Discov 4(12):977-987
72. Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol: Off J Am Soc Clin Oncol 10(6):1014-1024
73. Jiang XP, Yang DC, Elliott RL, Head JF (2000) Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. Cytokine 12(5):458-465
74. Jones RL, Giembycz MA, Woodward DF (2009) Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 158(1):104-145
75. Ma LZ, Walgren B, Clayton RA, Burkholder JR (2011 ) T.P. LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway. Paper presented at: Proceedings of the annual meeting of the American Association for Cancer Research; 2-6 Apr 2011, Orlando
76. Kaklamani VG, Hou N, Bian Y et al (2003) TGFBR16A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol: Off J Am Soc Clin Oncol 21(17):3236-3243
77. Kalaitzidis D, Gilmore TD (2005) Transcription factor cross-talk: the estrogen receptor and NFkappaB. Trends Endocrinology and Metabolism: TEM 16(2):46-52
78. Kallioniemi OP, Holli K, Vis akorpi T, Koivula T, Helin HH, Isola JJ (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. I J Cancer: J Int du Cancer 49(5):650-655
79. Kan CY, Iacopetta BJ, Lawson JS, Whitaker NJ (2005) Identification of human papillomavirus DNA gene sequences in human breast cancer. Br J Cancer 93(8):946-948
80. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS (2013) Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene, 11 Mar 2013
81. Kesson EM , Allardice GM, George WD, Burns HJ, Morrison DS (2012) Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13,722 women. BMJ 344:e2718
82. Kozlowski L Zakrzewska I Tokajuk P Wojtukiewicz MZ 2003 Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interl eukin-10 (IL-10) in blood serum of breast cancer patients Rocz Akad Med Bialymst 48: 82-84
83. Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS (2009) Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol 34(5):1209-1220
84. Lanza-Jacoby S, Miller S, Flynn J et al (2003) The cyclooxygenase-2 inhibitor, celecoxi b, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 12(12):1486-1491
85. Lei X, Bandyopadhyay A, Le T, Sun L (2002) Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 21(49):7514-7523
86. Lerebours F, Vacher S, Andrieu C et al (2008) NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8:41
87. Li J, Gonzalez-Angulo AM, Allen PK et al (2011) Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 16(12): 1675-1683
88. Lin Y, Huang R, Chen L et al (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer. J Int du Canc er 109(4):507-515
89. Liu CH, Chang SH, Narko K et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563-18569
90. Liu Y, Wang L, Lin XY et al (2012) Anti-apoptotic effect of claudin-1 on TNF-alpha-induced apoptosis in human breast cancer MCF-7 cells. Tumour Biol 33(6):2307-2315
91. Lyons TR, O'Br ien J, Borges VF et al (2011) Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17(9):1109-1115
92. Martin OA, Redon CE, Dickey JS, Nakamura AJ, Bonner WM (2011) Para-inflammation mediates systemic DNA damage in response to tumor growth. Communicative Integr Biol 4(1):78-81
93. Matsumoto G, Namekawa J, Muta M et al (2005) Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11(3):1287-1293
94. Matthews JR, Watson SM, Tevendale MC, Watson CJ, Clarke AR (2007) Caspase-dependent proteolytic cleavage of STAT3alpha in ES cells, in mammary glands undergoing forced involution and in breast cancer cell lines. BMC Cancer 7:29
95. Menter DG, Schilsky RL, DuBois RN (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clinical Cancer Res 16(5):1384-1390
96. Moody CA, Laimins LA (2009) Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog 5(10):e1000605
97. Moustakas A, Heldin CH ( 2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98(10):1512-1520
98. Muraoka-Cook RS, Kurokawa H, Koh Y et al (2004) Con ditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64(24):9002-9011
99. Murohashi M, Hinohara K, Kuroda M et al (2010) Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 102(1):206-212
100. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW J r (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17(7):3629-3639
101. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. New Engl J Med 367(19):1792-1802
102. Nishimura R, Nagao K, Miyayama H et al (2000) An analysis of serum interleukin-6 levels to predict benefits of medroxypro gesterone acetate in advanced or recurrent breast cancer. Oncology 59(2):166-173
103. Oshima M Dinchuk JE Kargman SL et al 1996 Suppression of intestinal polyposis in Apc delta716 knockout mice by i nhibition of cyclooxygenase 2 (COX-2 Cell 87 5 803-809
104. Pan Q, Kleer CG, van Golen KL et al (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62(17):4854-4859
105. Pan Q, Bao LW, Merajver SD (2003) Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 1(10):701-706
106. Pasche B, Kaklamani V, Hou N et al (2004) TGFBR16A and cancer: a meta-analysis of 12 casecontrol studies. J Clin Oncol 22(4):756-758
107. Pierga JY, Delaloge S, Espie M et al (2010) A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 122(2):429-437
108. Prasad S, Ravindran J, Aggarwal BB (2010) NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336(1-2):25-37
109. Psaty BM, Furberg CD (2005) COX-2 inhibitors-lessons in drug safety. New Engl J Med 352(11):1133-1135
110. Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117(Pt 8):1281-1283
111. Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632-635
112. Rivas MA, Carnevale RP, Proietti CJ et al (2008) TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAP K, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res 314(3):509-529
113. Robbins GF, Shah J, Rosen P, Chu F, Taylor J (1974) Inflammatory carcinoma of the breast. Surg Clin North Am 54(4):801-810
114. Robertson FM, Simeone AM, Mazumdar A et al (2008) Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast c ancer cells. J Exp Ther Oncol 7(4):299-312
115. Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cristofanilli M (2010) Differential regulation of the aggressive phenotype of inflammatory br east cancer cells by prostanoid receptors EP3 and EP4. Cancer 116(11):2806-2814
116. Rubio MF, Werbajh S, Cafferata EG et al (2006) TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dep endent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 25(9):1367-1377
117. Salgado R, Junius S, Benoy I et al (2003) Circulating interleukin-6 predicts survival in pati ents with metastatic breast cancer. Int J Cancer: J Int du Cancer 103(5):642-646
118. Sansone P, Storci G, Tavolari S et al (2007) IL-6 triggers malignant features in mammospheres from human ductal brea st carcinoma and normal mammary gland. J Clin Investig 117(12):3988-4002
119. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM (2007) Interleukin-6 is a potent growth factor fo r ER-alpha-positive human breast cancer. FASEB J: Off Publ Fed Am Soc Exp Biol 21(13):3763-3770
120. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF (1997) Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 43(3):211-215
121. Shostak K, Chariot A (2011) NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res: BCR 13(4):214
122. Simstein R, Burow M, Parker A, Weldon C, Beckman B (2003) Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 228(9):995-1003
123. Singh B, Cook KR, Martin C et al (2010) Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 27(4):233-240
124. Soliman AS, Kleer CG, Mrad K et al (2011) Inflammatory breast cancer in North Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco. Breast Dis 33(4) :159-169
125. Speirs V, Kerin MJ, Newton CJ et al (1999) Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. Int J Oncol 15(6):1251-1254
126. Studebaker AW, Storci G, Werbeck JL et al (2008) Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 6 8(21):9087-9095
127. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ et al (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277(21):18649-18657
128. Subramaniam V, Chakrabarti R, Prud'homme GJ, Jothy S (2010) Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anti-Cancer Drugs 21(4) :351-361
129. Subramaniam V, Ace O, Prud'homme GJ, Jothy S (2011) Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Exp Mol Pathol 90(1):116-122
130. Sullivan NJ, Sasser AK, Axel AE et al (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28(33):2940-2947
131. Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3:177-189
132. Thiery JP (2002) Epithelial-mesenchyma l transitions in tumour progression. Nat Rev Cancer 2(6):442-454
133. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890
134. Ueno NT, Buzdar AU, Singletary SE et al (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40(4):321-329
135. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD (2000) RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2(5):418-425
136. Van Laere S, Van der Auwera I, Van den Eynden GG et al (2005) Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 93(3):237-246
137. Van Laere SJ, Van der Auwera I, Van den Eynden GG et al (2007) NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hype ractivation. Br J Cancer 97(5):659-669
138. Van Laere S, Limame R, Van Marck EA, Vermeulen PB, Dirix LY (2010) Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiment s. Cancer 116(11 Suppl):2794-2805
139. Walter M, Liang S, Ghosh S, Hornsby PJ, Li R (2009) Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28(30):2745-2755
140. Wang D, Dubois RN (2004) Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31(1 Suppl 3):64-73
141. Wang FM, Liu HQ, Liu SR, Tang SP, Yang L, Feng GS (2005) SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro. Breast Cancer Res Treat 89(1):5-14
142. Weaver KL, Ivester P, Seeds M, Case LD, Arm JP, Chilton FH (2009) Effect of dietary fatty acids on inflammatory gene expression in healthy humans. J Biol Chem 284(23):15400-15407
143. Wendel M, Heller AR (2009) Anticancer actions of omega-3 fatty acids-current state and future perspectives. Anti-Cancer Agents Med Chem 9(4):457-470
144. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908-7916
145. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH (2008) The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 173(2):561-574
146. Xu J Lamouille S Derynck R 2009 TGF-beta-induced epithelial to mesenchymal transition Cell Res 19 2)156-172
147. Yang EY, Moses HL (1990) Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111(2):731-7 41
148. Yang Y, Pan X, Lei W, Wang J, Song J (2006) Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 25(55): 7235-7244
149. Yang WT, Le-Petross HT, Macapinlac H et al (2008) Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 109(3):417-426
150. Yao C, Lin Y, Chua MS et al (2007) Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer: J Int du Cancer 121(9):1949-1957
151. Yin Y, Chen X, Shu Y (2009) Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacotherapie 63(6):421-428
152. Yoshimura N, Sano H, Okamoto M et al (2003) Expression of cyclooxygenase-1 and-2 in human breast cancer. Surg Today 33(11):805-811
153. Yu Y, Wang Y, Ren X et al (2010) Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells. Mol Cancer Res 8(12):1633-1642
154. Zhang GJ, Adachi I (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anti-Cancer Res 19(2B):1427-1432
155. Zhang F, Lundin M, Ristimaki A et al (2003) Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 63(16):5005-5010
156. Zhang SM, Lin J, Cook NR et al (2007) C-reactive protein and risk of breast cancer. J Natl Cancer Inst 99(11):890-894
157. Zhang D, LaFortune TA, Krishnamurthy S et al (2009) Epidermal growth factor receptor tyrosine kina se inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 15(21):6639-6648
158. Zhou BP, Hu MC, Miller SA et al ( 2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275(11):8027-8031
159. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y (2008) NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111(3):419-427